Cigna Corporation

(New York Stock Exchange)
Back to all articles
Bullish +65

Cigna boosts 2026 outlook as insurance, specialty pharmacy profits climb

Company update Earnings report Guidance raised AI-generated analysis

πŸ“ˆ Cigna boosted its 2026 outlook for adjusted income from operations to at least $30.60 per share, marking the third annual increase.

πŸ’° The company reported net income of $1.4 billion on revenue of $73.7 billion in the quarter, exceeding analyst expectations.

πŸ“Š Cigna Healthcare drove bulk upside with adjusted operating income up 15% year over year to $1.2 billion despite elevated medical costs.

πŸ’Š Specialty pharmacy earnings surged 15% year over year as adoption of cheaper biosimilars and generics accelerated.

πŸ”„ Express Scripts adjusted operating income fell 22% year over year due to heavy spending on transitioning to the new Signature model.

πŸ“‰ The medical loss ratio for Cigna Healthcare was 85%, slightly higher than last year but better than analyst expectations.

πŸš€ CEO Brian Evanko stated the company is well-positioned for profitable growth in 2027 with improving stop-loss margins.

βš–οΈ Cigna faces regulatory headwinds as it navigates new Department of Labor transparency rules and potential PBM breakup proposals.

πŸ“‰ Express Scripts will face financial pressure from the industry-wide shift away from rebates and shrinking employer GLP-1 coverage.

πŸ₯ Cigna is set to exit the Affordable Care Act exchanges, which will remove contribution from that specific business line.

Bullish Signals
  • Cigna boosted its 2026 outlook for adjusted income from operations to at least $30.60 per share, up from the previous guidance of $30.45.
  • The company reported net income of $1.4 billion on revenue of $73.7 billion in the quarter, beating analyst expectations.
  • Cigna Healthcare adjusted operating income increased 15% year over year to $1.2 billion driven by improved operational efficiencies and higher investment income.
  • Specialty pharmacy earnings rose 15% year over year despite only a 1% revenue increase, fueled by stronger adoption of cheaper biosimilar and specialty generic drugs.
  • Cigna's stock price rose 3% following the release of third-quarter results that exceeded Wall Street expectations.
  • CEO Brian Evanko highlighted that deliberate portfolio shaping over several years is delivering tangible financial results.
Risk Factors
  • Express Scripts adjusted operating income declined 22% year over year as the company spends heavily to transition to a new pharmacy benefits model called Signature.
  • The medical loss ratio for Cigna Healthcare was 85%, which is slightly higher than the 84.8% recorded in the same quarter last year.
  • Express Scripts faces financial pressure related to the industrywide shift away from rebates and shrinking employer coverage of GLP-1s for weight loss.
  • Cigna's specialty division faces a more limited pipeline for biosimilar and specialty generic launches according to executives.
  • The company is set to exit the Affordable Care Act exchanges, which will remove the contribution from that business line.
  • Growing regulatory scrutiny on PBMs includes efforts at state and federal levels to reform the industry, with some calling for vertically consolidated behemoths to be broken up.
Full Analysis
Cigna Group (CI) reported a strong third quarter with net income of $1.4 billion on revenue of $73.7 billion, beating analyst expectations. While year-over-year net income declined to $1.9 billion from the prior year, adjusted earnings per share and adjusted operating income both increased, reflecting improved operational efficiencies and higher investment income. The company's stock rose 3% following the announcement. Cigna Healthcare, covering 18.5 million people, drove significant upside with an adjusted operating income of $1.2 billion, up 15% year over year. This growth was achieved despite elevated medical costs, which were more than offset by premium hikes secured earlier in the year. The division maintained a medical loss ratio of 85%, slightly better than analyst expectations. The company significantly boosted its 2026 financial outlook for the third time this year, raising adjusted income from operations guidance to at least $30.60 per share. CEO Brian Evanko highlighted strong performance in specialty pharmacy and expressed confidence in profitable growth for 2027, citing improving stop-loss margins and productivity initiatives. However, the PBM segment faced headwinds due to a transition to a new transparency model called Signature. Cigna's Specialty segment saw earnings rise 15% year over year, driven by the adoption of cheaper biosimilars and generics, with Revlimid penetration reaching approximately 90%. Conversely, Express Scripts reported adjusted operating income down 22% as it incurs heavy costs to transition its pharmacy benefits model. The company also faces regulatory scrutiny regarding PBM consolidation and upcoming changes in GLP-1 coverage.